Heide Ford
Concepts (410)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Homeodomain Proteins | 31 | 2026 | 523 | 7.300 |
Why?
| | Protein Tyrosine Phosphatases | 23 | 2026 | 167 | 5.410 |
Why?
| | Epithelial-Mesenchymal Transition | 13 | 2025 | 219 | 3.440 |
Why?
| | Breast Neoplasms | 27 | 2025 | 2447 | 3.420 |
Why?
| | Gene Expression Regulation, Neoplastic | 29 | 2025 | 1455 | 3.120 |
Why?
| | Intracellular Signaling Peptides and Proteins | 17 | 2026 | 459 | 2.700 |
Why?
| | Nuclear Proteins | 17 | 2026 | 748 | 2.590 |
Why?
| | Triple Negative Breast Neoplasms | 6 | 2025 | 215 | 2.310 |
Why?
| | Cell Line, Tumor | 41 | 2026 | 3539 | 2.000 |
Why?
| | Transforming Growth Factor beta | 7 | 2012 | 479 | 1.940 |
Why?
| | Neoplasm Metastasis | 17 | 2025 | 688 | 1.920 |
Why?
| | Neoplasms | 17 | 2025 | 2870 | 1.880 |
Why?
| | Neoplastic Stem Cells | 10 | 2025 | 412 | 1.850 |
Why?
| | MicroRNAs | 6 | 2018 | 700 | 1.640 |
Why?
| | TNF-Related Apoptosis-Inducing Ligand | 6 | 2017 | 54 | 1.500 |
Why?
| | Vascular Endothelial Growth Factor C | 3 | 2020 | 16 | 1.460 |
Why?
| | Drug Resistance, Neoplasm | 10 | 2026 | 881 | 1.310 |
Why?
| | Cell Transformation, Neoplastic | 6 | 2015 | 339 | 1.290 |
Why?
| | Signal Transduction | 20 | 2025 | 5221 | 1.190 |
Why?
| | Muscle Development | 2 | 2022 | 115 | 1.070 |
Why?
| | DNA-Binding Proteins | 7 | 2025 | 1497 | 1.060 |
Why?
| | Sarcoma, Ewing | 2 | 2023 | 102 | 1.060 |
Why?
| | Up-Regulation | 9 | 2018 | 851 | 1.000 |
Why?
| | Protein Phosphatase 2 | 3 | 2025 | 41 | 0.960 |
Why?
| | Cell Plasticity | 2 | 2025 | 37 | 0.910 |
Why?
| | Transcription Factors | 7 | 2022 | 1739 | 0.900 |
Why?
| | Zebrafish Proteins | 2 | 2022 | 311 | 0.890 |
Why?
| | Rhabdomyosarcoma | 2 | 2024 | 64 | 0.880 |
Why?
| | Mammary Glands, Human | 4 | 2010 | 67 | 0.880 |
Why?
| | Chemokine CCL2 | 1 | 2025 | 115 | 0.870 |
Why?
| | Animals | 52 | 2026 | 38030 | 0.860 |
Why?
| | Oncogene Proteins, Fusion | 4 | 2024 | 210 | 0.830 |
Why?
| | Disease Progression | 5 | 2025 | 2840 | 0.800 |
Why?
| | Proto-Oncogene Proteins c-myc | 3 | 2025 | 167 | 0.730 |
Why?
| | Killer Cells, Natural | 1 | 2025 | 467 | 0.700 |
Why?
| | Cerebellar Neoplasms | 1 | 2023 | 177 | 0.690 |
Why?
| | NF-kappa B | 1 | 2025 | 661 | 0.680 |
Why?
| | Medulloblastoma | 1 | 2023 | 215 | 0.680 |
Why?
| | Receptors, TNF-Related Apoptosis-Inducing Ligand | 3 | 2017 | 31 | 0.670 |
Why?
| | Neuropilin-2 | 1 | 2020 | 4 | 0.670 |
Why?
| | Antineoplastic Agents | 9 | 2024 | 2192 | 0.660 |
Why?
| | Mammary Neoplasms, Experimental | 5 | 2012 | 70 | 0.660 |
Why?
| | Mice | 31 | 2026 | 18329 | 0.640 |
Why?
| | Cell Transdifferentiation | 2 | 2010 | 31 | 0.630 |
Why?
| | Humans | 78 | 2026 | 144261 | 0.620 |
Why?
| | Mice, SCID | 9 | 2019 | 369 | 0.610 |
Why?
| | Cadherins | 2 | 2014 | 200 | 0.610 |
Why?
| | Breast | 1 | 2020 | 157 | 0.600 |
Why?
| | Pluripotent Stem Cells | 1 | 2020 | 84 | 0.590 |
Why?
| | Cell Differentiation | 10 | 2026 | 2048 | 0.590 |
Why?
| | Proto-Oncogene Proteins c-mdm2 | 2 | 2016 | 66 | 0.580 |
Why?
| | Proto-Oncogene Protein c-fli-1 | 2 | 2023 | 29 | 0.570 |
Why?
| | RNA-Binding Protein EWS | 2 | 2023 | 30 | 0.570 |
Why?
| | Transcriptional Activation | 3 | 2018 | 382 | 0.560 |
Why?
| | Nedd4 Ubiquitin Protein Ligases | 1 | 2018 | 15 | 0.560 |
Why?
| | Neoplasm Proteins | 3 | 2018 | 442 | 0.560 |
Why?
| | SOXB1 Transcription Factors | 1 | 2019 | 67 | 0.550 |
Why?
| | Epithelial Cells | 5 | 2012 | 1125 | 0.540 |
Why?
| | Receptor, Notch1 | 1 | 2018 | 64 | 0.540 |
Why?
| | Zinc Finger Protein GLI1 | 1 | 2017 | 26 | 0.520 |
Why?
| | Mice, Inbred NOD | 6 | 2019 | 610 | 0.520 |
Why?
| | Cell Proliferation | 12 | 2024 | 2494 | 0.510 |
Why?
| | Anion Transport Proteins | 1 | 2017 | 8 | 0.510 |
Why?
| | Paracrine Communication | 1 | 2017 | 67 | 0.500 |
Why?
| | Down-Regulation | 2 | 2015 | 627 | 0.490 |
Why?
| | Female | 37 | 2025 | 77976 | 0.490 |
Why?
| | Genetic Heterogeneity | 1 | 2016 | 62 | 0.480 |
Why?
| | B7-H1 Antigen | 1 | 2018 | 241 | 0.470 |
Why?
| | Ribosomal Proteins | 1 | 2015 | 91 | 0.450 |
Why?
| | Twist-Related Protein 1 | 1 | 2015 | 9 | 0.450 |
Why?
| | Gene Regulatory Networks | 3 | 2026 | 318 | 0.450 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2019 | 1137 | 0.440 |
Why?
| | Mammary Glands, Animal | 3 | 2010 | 128 | 0.440 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2016 | 529 | 0.440 |
Why?
| | Nerve Tissue Proteins | 1 | 2019 | 592 | 0.440 |
Why?
| | Cell Cycle | 4 | 2013 | 596 | 0.440 |
Why?
| | Mesoderm | 3 | 2009 | 150 | 0.420 |
Why?
| | Epithelium | 3 | 2009 | 314 | 0.420 |
Why?
| | Retina | 2 | 2026 | 323 | 0.410 |
Why?
| | Tumor Microenvironment | 3 | 2025 | 732 | 0.410 |
Why?
| | Receptors, Transforming Growth Factor beta | 2 | 2012 | 57 | 0.410 |
Why?
| | Neoplasm Transplantation | 6 | 2014 | 251 | 0.410 |
Why?
| | Protein Binding | 9 | 2025 | 2270 | 0.400 |
Why?
| | MCF-7 Cells | 4 | 2020 | 135 | 0.400 |
Why?
| | Branchio-Oto-Renal Syndrome | 2 | 2013 | 7 | 0.400 |
Why?
| | Interferons | 2 | 2025 | 188 | 0.400 |
Why?
| | Molecular Targeted Therapy | 2 | 2015 | 431 | 0.380 |
Why?
| | Lung Neoplasms | 4 | 2019 | 2637 | 0.380 |
Why?
| | Transcription, Genetic | 3 | 2014 | 1495 | 0.380 |
Why?
| | Superoxide Dismutase | 1 | 2014 | 301 | 0.370 |
Why?
| | Small Molecule Libraries | 3 | 2025 | 110 | 0.370 |
Why?
| | Gene Expression Regulation, Developmental | 5 | 2017 | 905 | 0.370 |
Why?
| | Lymphangiogenesis | 1 | 2012 | 27 | 0.360 |
Why?
| | Genes, Tumor Suppressor | 1 | 2012 | 82 | 0.360 |
Why?
| | Smad7 Protein | 1 | 2012 | 20 | 0.360 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2012 | 173 | 0.350 |
Why?
| | Mice, Nude | 7 | 2017 | 682 | 0.330 |
Why?
| | Genes, Homeobox | 3 | 2022 | 50 | 0.320 |
Why?
| | Apoptosis | 4 | 2019 | 2430 | 0.310 |
Why?
| | Bone Neoplasms | 1 | 2012 | 253 | 0.300 |
Why?
| | Cyclin A | 3 | 2009 | 18 | 0.300 |
Why?
| | Mice, Inbred BALB C | 4 | 2019 | 1253 | 0.300 |
Why?
| | Embryonic Development | 1 | 2010 | 125 | 0.300 |
Why?
| | Enzyme Inhibitors | 7 | 2024 | 824 | 0.300 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2025 | 928 | 0.280 |
Why?
| | Prognosis | 6 | 2019 | 4278 | 0.270 |
Why?
| | Cell Movement | 5 | 2020 | 965 | 0.270 |
Why?
| | Tyrosine | 3 | 2024 | 221 | 0.270 |
Why?
| | Genomic Instability | 1 | 2008 | 66 | 0.260 |
Why?
| | Cell Hypoxia | 2 | 2025 | 247 | 0.250 |
Why?
| | Ovarian Neoplasms | 3 | 2012 | 586 | 0.240 |
Why?
| | Synthetic Lethal Mutations | 1 | 2026 | 4 | 0.240 |
Why?
| | Heterografts | 3 | 2017 | 143 | 0.240 |
Why?
| | Eukaryotic Initiation Factor-3 | 1 | 2025 | 10 | 0.240 |
Why?
| | Central Nervous System Neoplasms | 2 | 2026 | 173 | 0.230 |
Why?
| | Gene Knockdown Techniques | 3 | 2016 | 336 | 0.220 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2012 | 1953 | 0.220 |
Why?
| | STAT1 Transcription Factor | 1 | 2025 | 68 | 0.220 |
Why?
| | Cell Survival | 3 | 2026 | 1098 | 0.220 |
Why?
| | Proto-Oncogene Protein c-ets-1 | 1 | 2024 | 26 | 0.220 |
Why?
| | Gene Amplification | 1 | 2005 | 120 | 0.210 |
Why?
| | Neoplasm Invasiveness | 3 | 2024 | 508 | 0.210 |
Why?
| | rhoA GTP-Binding Protein | 1 | 2024 | 76 | 0.210 |
Why?
| | Myosins | 1 | 2024 | 136 | 0.210 |
Why?
| | Rosaniline Dyes | 1 | 2024 | 15 | 0.210 |
Why?
| | Protein Biosynthesis | 2 | 2025 | 458 | 0.200 |
Why?
| | Zebrafish | 2 | 2022 | 528 | 0.200 |
Why?
| | Kaplan-Meier Estimate | 2 | 2020 | 964 | 0.200 |
Why?
| | Protein Stability | 2 | 2018 | 178 | 0.200 |
Why?
| | Eye Proteins | 1 | 2024 | 90 | 0.200 |
Why?
| | Peptides | 3 | 2025 | 995 | 0.200 |
Why?
| | Drug Design | 1 | 2024 | 173 | 0.200 |
Why?
| | Gene Expression Profiling | 4 | 2012 | 1782 | 0.190 |
Why?
| | Integrins | 1 | 2023 | 89 | 0.190 |
Why?
| | Mitochondrial Proteins | 1 | 2024 | 261 | 0.190 |
Why?
| | Proto-Oncogene Proteins | 1 | 2026 | 623 | 0.180 |
Why?
| | Immunohistochemistry | 3 | 2018 | 1715 | 0.180 |
Why?
| | Models, Biological | 4 | 2017 | 1820 | 0.180 |
Why?
| | Myogenin | 1 | 2022 | 15 | 0.180 |
Why?
| | Rhabdomyosarcoma, Embryonal | 1 | 2022 | 16 | 0.180 |
Why?
| | MyoD Protein | 1 | 2022 | 31 | 0.180 |
Why?
| | Glioblastoma | 2 | 2026 | 353 | 0.180 |
Why?
| | HEK293 Cells | 3 | 2024 | 744 | 0.180 |
Why?
| | Cell Cycle Proteins | 1 | 2026 | 628 | 0.180 |
Why?
| | Transplantation, Heterologous | 4 | 2012 | 193 | 0.170 |
Why?
| | Tumor Cells, Cultured | 4 | 2019 | 919 | 0.170 |
Why?
| | Brain Neoplasms | 3 | 2024 | 1318 | 0.170 |
Why?
| | Trans-Activators | 3 | 2026 | 405 | 0.160 |
Why?
| | Cell Dedifferentiation | 2 | 2010 | 32 | 0.160 |
Why?
| | Chromatin | 1 | 2024 | 561 | 0.160 |
Why?
| | BRCA1 Protein | 1 | 2020 | 81 | 0.150 |
Why?
| | Hedgehog Proteins | 1 | 2020 | 197 | 0.150 |
Why?
| | Prostatic Neoplasms | 2 | 2024 | 974 | 0.150 |
Why?
| | Nanog Homeobox Protein | 1 | 2019 | 14 | 0.150 |
Why?
| | Oxygen | 1 | 2024 | 995 | 0.150 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2026 | 682 | 0.140 |
Why?
| | Phosphorylation | 3 | 2024 | 1732 | 0.140 |
Why?
| | Cyclin A1 | 3 | 2009 | 5 | 0.140 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 4 | 2011 | 981 | 0.140 |
Why?
| | Antigens, CD | 2 | 2014 | 555 | 0.140 |
Why?
| | Mutation | 1 | 2009 | 4085 | 0.130 |
Why?
| | Cell Growth Processes | 2 | 2008 | 50 | 0.130 |
Why?
| | Blotting, Western | 3 | 2011 | 1187 | 0.130 |
Why?
| | RNA, Small Interfering | 2 | 2017 | 634 | 0.130 |
Why?
| | Veratrum Alkaloids | 1 | 2017 | 20 | 0.130 |
Why?
| | Maxilla | 1 | 2017 | 36 | 0.130 |
Why?
| | DNA Damage | 3 | 2026 | 428 | 0.130 |
Why?
| | Basigin | 1 | 2017 | 24 | 0.130 |
Why?
| | RNA, Messenger | 3 | 2018 | 2829 | 0.130 |
Why?
| | Proteolysis | 2 | 2017 | 173 | 0.120 |
Why?
| | Carbolines | 1 | 1996 | 35 | 0.120 |
Why?
| | Oxidoreductases Acting on CH-CH Group Donors | 1 | 1996 | 27 | 0.120 |
Why?
| | Promoter Regions, Genetic | 3 | 2010 | 1255 | 0.120 |
Why?
| | Protein Structure, Tertiary | 2 | 2009 | 862 | 0.120 |
Why?
| | Cellular Reprogramming | 1 | 2017 | 103 | 0.120 |
Why?
| | Clone Cells | 1 | 2016 | 266 | 0.120 |
Why?
| | Biphenyl Compounds | 1 | 1996 | 68 | 0.120 |
Why?
| | Multigene Family | 2 | 2008 | 203 | 0.120 |
Why?
| | Oxidoreductases | 1 | 1996 | 96 | 0.120 |
Why?
| | Membrane Transport Proteins | 1 | 2017 | 154 | 0.120 |
Why?
| | Allosteric Regulation | 3 | 2024 | 97 | 0.120 |
Why?
| | Endothelin-1 | 1 | 2017 | 184 | 0.110 |
Why?
| | Epigenesis, Genetic | 2 | 2024 | 684 | 0.110 |
Why?
| | Cytidine | 2 | 1993 | 9 | 0.110 |
Why?
| | Tumor Burden | 2 | 2017 | 319 | 0.110 |
Why?
| | Zinc Finger E-box Binding Homeobox 2 | 1 | 2014 | 6 | 0.110 |
Why?
| | Structure-Activity Relationship | 3 | 2024 | 567 | 0.110 |
Why?
| | Receptors, Estrogen | 1 | 2018 | 457 | 0.110 |
Why?
| | Claudins | 1 | 2014 | 23 | 0.110 |
Why?
| | Cell Nucleus | 2 | 2009 | 618 | 0.110 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 1 | 2015 | 128 | 0.110 |
Why?
| | Idiopathic Pulmonary Fibrosis | 1 | 2022 | 691 | 0.110 |
Why?
| | Mass Spectrometry | 1 | 2018 | 744 | 0.110 |
Why?
| | Gene Expression | 3 | 2009 | 1487 | 0.110 |
Why?
| | RNA Processing, Post-Transcriptional | 1 | 2015 | 92 | 0.100 |
Why?
| | Genes, MHC Class I | 2 | 2005 | 36 | 0.100 |
Why?
| | Autophagy | 1 | 2016 | 285 | 0.100 |
Why?
| | Aldehyde Dehydrogenase | 1 | 2014 | 99 | 0.100 |
Why?
| | Gene Expression Regulation | 1 | 2023 | 2603 | 0.100 |
Why?
| | RNA Interference | 2 | 2017 | 476 | 0.100 |
Why?
| | Transfection | 3 | 2017 | 938 | 0.100 |
Why?
| | Survival Rate | 1 | 2019 | 2088 | 0.100 |
Why?
| | G1 Phase | 1 | 2013 | 66 | 0.100 |
Why?
| | Biomedical Research | 1 | 2020 | 709 | 0.100 |
Why?
| | Pyrimidines | 1 | 2017 | 532 | 0.100 |
Why?
| | Child | 2 | 2023 | 22537 | 0.100 |
Why?
| | Cyclin-Dependent Kinase 6 | 1 | 2013 | 49 | 0.100 |
Why?
| | Amino Acid Sequence | 6 | 2014 | 2154 | 0.100 |
Why?
| | Cluster Analysis | 2 | 2012 | 519 | 0.090 |
Why?
| | Pyridines | 1 | 2017 | 605 | 0.090 |
Why?
| | Disease-Free Survival | 1 | 2014 | 768 | 0.090 |
Why?
| | Antibodies, Neoplasm | 1 | 2012 | 34 | 0.090 |
Why?
| | Neuroglia | 1 | 2013 | 172 | 0.090 |
Why?
| | Etoposide | 1 | 2012 | 166 | 0.090 |
Why?
| | Oligonucleotide Array Sequence Analysis | 2 | 2012 | 758 | 0.090 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2018 | 917 | 0.090 |
Why?
| | Biomarkers, Tumor | 1 | 2019 | 1313 | 0.090 |
Why?
| | Reactive Oxygen Species | 1 | 2014 | 621 | 0.090 |
Why?
| | Proteasome Endopeptidase Complex | 2 | 2017 | 159 | 0.090 |
Why?
| | Tissue Array Analysis | 1 | 2011 | 50 | 0.090 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2024 | 2026 | 0.090 |
Why?
| | Repressor Proteins | 1 | 2014 | 437 | 0.080 |
Why?
| | Metabolic Networks and Pathways | 1 | 2012 | 187 | 0.080 |
Why?
| | Proteasome Inhibitors | 1 | 2011 | 40 | 0.080 |
Why?
| | Cell Death | 2 | 2021 | 383 | 0.080 |
Why?
| | Antioxidants | 1 | 2014 | 549 | 0.080 |
Why?
| | Lymphatic Metastasis | 1 | 2012 | 333 | 0.080 |
Why?
| | Energy Metabolism | 1 | 2017 | 935 | 0.080 |
Why?
| | Antigens, Differentiation | 1 | 2010 | 77 | 0.080 |
Why?
| | Protein Domains | 2 | 2024 | 313 | 0.080 |
Why?
| | Doxorubicin | 1 | 2012 | 397 | 0.080 |
Why?
| | DNA Repair | 2 | 2026 | 255 | 0.080 |
Why?
| | Metaplasia | 1 | 2009 | 57 | 0.080 |
Why?
| | Smad3 Protein | 1 | 2009 | 43 | 0.080 |
Why?
| | Salivary Proteins and Peptides | 1 | 2009 | 14 | 0.070 |
Why?
| | Lymphocytes | 1 | 1991 | 382 | 0.070 |
Why?
| | Follow-Up Studies | 1 | 2019 | 5389 | 0.070 |
Why?
| | Lymphoma | 1 | 2011 | 232 | 0.070 |
Why?
| | Submandibular Gland | 1 | 2009 | 20 | 0.070 |
Why?
| | Mutant Proteins | 1 | 2009 | 106 | 0.070 |
Why?
| | Glioma | 1 | 2013 | 425 | 0.070 |
Why?
| | Lactation | 1 | 2010 | 192 | 0.070 |
Why?
| | Pancreatic Neoplasms | 1 | 2017 | 918 | 0.070 |
Why?
| | Protein Structure, Secondary | 1 | 2009 | 369 | 0.070 |
Why?
| | Amino Acid Substitution | 1 | 2009 | 304 | 0.070 |
Why?
| | Eye Neoplasms | 1 | 2008 | 30 | 0.070 |
Why?
| | NIH 3T3 Cells | 1 | 2008 | 148 | 0.070 |
Why?
| | Clinical Trials as Topic | 2 | 2012 | 1050 | 0.070 |
Why?
| | Oxidative Stress | 1 | 2014 | 1339 | 0.070 |
Why?
| | Cell Line | 3 | 2014 | 2879 | 0.070 |
Why?
| | Protein Transport | 1 | 2009 | 441 | 0.070 |
Why?
| | Ubiquitin | 1 | 2006 | 86 | 0.060 |
Why?
| | Myeloid Ecotropic Viral Integration Site 1 Protein | 1 | 2026 | 11 | 0.060 |
Why?
| | Amino Acid Motifs | 1 | 2006 | 224 | 0.060 |
Why?
| | DNA | 2 | 2009 | 1460 | 0.060 |
Why?
| | Models, Molecular | 4 | 2019 | 1618 | 0.060 |
Why?
| | Crystallography, X-Ray | 2 | 2019 | 492 | 0.060 |
Why?
| | Disease Models, Animal | 2 | 2012 | 4556 | 0.060 |
Why?
| | Chromosomes, Human, Pair 14 | 1 | 2005 | 21 | 0.060 |
Why?
| | Antigens, CD1 | 1 | 2005 | 60 | 0.060 |
Why?
| | Ovary | 1 | 2007 | 228 | 0.060 |
Why?
| | Myeloid-Lymphoid Leukemia Protein | 1 | 2026 | 72 | 0.060 |
Why?
| | Chickens | 1 | 2005 | 191 | 0.050 |
Why?
| | PAX3 Transcription Factor | 1 | 2024 | 17 | 0.050 |
Why?
| | Molecular Structure | 2 | 2024 | 498 | 0.050 |
Why?
| | Endoplasmic Reticulum Stress | 1 | 2025 | 120 | 0.050 |
Why?
| | Paired Box Transcription Factors | 1 | 2024 | 43 | 0.050 |
Why?
| | Precipitin Tests | 1 | 2004 | 93 | 0.050 |
Why?
| | Mice, Transgenic | 1 | 2009 | 2182 | 0.050 |
Why?
| | Jumonji Domain-Containing Histone Demethylases | 1 | 2024 | 64 | 0.050 |
Why?
| | Cryoelectron Microscopy | 1 | 2025 | 222 | 0.050 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 2024 | 191 | 0.050 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2025 | 297 | 0.050 |
Why?
| | Phylogeny | 2 | 2005 | 1015 | 0.050 |
Why?
| | CCAAT-Enhancer-Binding Protein-beta | 1 | 2003 | 33 | 0.050 |
Why?
| | Dogfish | 1 | 2003 | 4 | 0.050 |
Why?
| | Cyclin D1 | 1 | 2003 | 61 | 0.050 |
Why?
| | Cell Lineage | 1 | 2025 | 376 | 0.050 |
Why?
| | Molecular Sequence Data | 5 | 2014 | 2929 | 0.050 |
Why?
| | DNA, Complementary | 1 | 2003 | 276 | 0.050 |
Why?
| | Sequence Analysis, RNA | 1 | 2025 | 442 | 0.050 |
Why?
| | Cell Division | 1 | 2004 | 766 | 0.050 |
Why?
| | Fibroblasts | 1 | 2008 | 1032 | 0.050 |
Why?
| | Neovascularization, Pathologic | 1 | 2004 | 286 | 0.040 |
Why?
| | Mice, Inbred C57BL | 2 | 2010 | 5988 | 0.040 |
Why?
| | Single-Cell Analysis | 1 | 2025 | 356 | 0.040 |
Why?
| | Evolution, Molecular | 1 | 2005 | 513 | 0.040 |
Why?
| | Kinetics | 2 | 2012 | 1627 | 0.040 |
Why?
| | Developmental Biology | 1 | 2020 | 23 | 0.040 |
Why?
| | Neural Stem Cells | 1 | 2021 | 166 | 0.040 |
Why?
| | Fibrosis | 1 | 2022 | 547 | 0.040 |
Why?
| | Sequence Homology, Amino Acid | 2 | 2014 | 396 | 0.040 |
Why?
| | Terminology as Topic | 1 | 2020 | 255 | 0.030 |
Why?
| | Consensus | 1 | 2020 | 488 | 0.030 |
Why?
| | Sp7 Transcription Factor | 1 | 2017 | 7 | 0.030 |
Why?
| | Zygoma | 1 | 2017 | 7 | 0.030 |
Why?
| | Serrate-Jagged Proteins | 1 | 2017 | 27 | 0.030 |
Why?
| | Branchial Region | 1 | 2017 | 37 | 0.030 |
Why?
| | Monocarboxylic Acid Transporters | 1 | 2017 | 21 | 0.030 |
Why?
| | Plasma Membrane Calcium-Transporting ATPases | 1 | 2017 | 10 | 0.030 |
Why?
| | Receptor, Endothelin A | 1 | 2017 | 63 | 0.030 |
Why?
| | Male | 6 | 2024 | 72035 | 0.030 |
Why?
| | Treatment Outcome | 1 | 2012 | 11643 | 0.030 |
Why?
| | Quinaldines | 1 | 1996 | 1 | 0.030 |
Why?
| | Orotic Acid | 1 | 1996 | 3 | 0.030 |
Why?
| | Pregnancy | 1 | 2010 | 7180 | 0.030 |
Why?
| | Craniofacial Abnormalities | 1 | 2017 | 76 | 0.030 |
Why?
| | Autophagy-Related Proteins | 1 | 2016 | 46 | 0.030 |
Why?
| | DNA Primers | 3 | 2005 | 511 | 0.030 |
Why?
| | Diphtheria Toxin | 1 | 2016 | 65 | 0.030 |
Why?
| | Receptors, Notch | 1 | 2017 | 92 | 0.030 |
Why?
| | Ribonucleotides | 1 | 1996 | 26 | 0.030 |
Why?
| | Body Patterning | 1 | 2017 | 138 | 0.030 |
Why?
| | Integrases | 1 | 2017 | 122 | 0.030 |
Why?
| | Embryo, Mammalian | 1 | 2017 | 232 | 0.030 |
Why?
| | Phosphotyrosine | 1 | 1996 | 39 | 0.030 |
Why?
| | Epidermal Growth Factor | 1 | 2016 | 171 | 0.030 |
Why?
| | Neural Crest | 1 | 2017 | 126 | 0.030 |
Why?
| | Aspartic Acid | 1 | 1996 | 88 | 0.030 |
Why?
| | Sodium Bicarbonate | 1 | 1996 | 47 | 0.030 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2017 | 269 | 0.030 |
Why?
| | Statistics, Nonparametric | 2 | 2009 | 427 | 0.030 |
Why?
| | Cytidine Triphosphate | 2 | 1993 | 19 | 0.030 |
Why?
| | Cell Adhesion | 1 | 2017 | 454 | 0.030 |
Why?
| | Green Fluorescent Proteins | 1 | 2016 | 405 | 0.030 |
Why?
| | Calcium Signaling | 1 | 2017 | 251 | 0.030 |
Why?
| | Adult | 3 | 2015 | 40262 | 0.030 |
Why?
| | Spectrophotometry, Ultraviolet | 1 | 2014 | 85 | 0.030 |
Why?
| | Carbon-Nitrogen Ligases | 1 | 1993 | 5 | 0.030 |
Why?
| | Leukemia L1210 | 1 | 1993 | 7 | 0.030 |
Why?
| | Calorimetry | 1 | 2014 | 72 | 0.030 |
Why?
| | Leukemia | 1 | 1996 | 245 | 0.030 |
Why?
| | Colonic Neoplasms | 1 | 1996 | 259 | 0.030 |
Why?
| | Molecular Docking Simulation | 1 | 2014 | 123 | 0.030 |
Why?
| | Recombinant Fusion Proteins | 1 | 2016 | 674 | 0.030 |
Why?
| | Zinc Finger E-box-Binding Homeobox 1 | 1 | 2013 | 23 | 0.030 |
Why?
| | Magnesium | 1 | 2014 | 155 | 0.030 |
Why?
| | Amino Acids | 1 | 2017 | 521 | 0.020 |
Why?
| | Phenylhydrazines | 1 | 2012 | 4 | 0.020 |
Why?
| | Miniaturization | 1 | 2012 | 22 | 0.020 |
Why?
| | Protein Phosphatase 2C | 1 | 2012 | 15 | 0.020 |
Why?
| | Fluoresceins | 1 | 2012 | 48 | 0.020 |
Why?
| | Enzyme Assays | 1 | 2012 | 25 | 0.020 |
Why?
| | Phosphoprotein Phosphatases | 1 | 2012 | 65 | 0.020 |
Why?
| | Time Factors | 2 | 2017 | 7155 | 0.020 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 1 | 2012 | 44 | 0.020 |
Why?
| | Spleen | 2 | 2005 | 508 | 0.020 |
Why?
| | Spectrometry, Fluorescence | 1 | 2012 | 168 | 0.020 |
Why?
| | Kidney Neoplasms | 1 | 1996 | 412 | 0.020 |
Why?
| | Antibody Specificity | 1 | 2012 | 181 | 0.020 |
Why?
| | Nuclear Magnetic Resonance, Biomolecular | 1 | 2014 | 346 | 0.020 |
Why?
| | DNA Fragmentation | 1 | 2011 | 39 | 0.020 |
Why?
| | Mutation, Missense | 1 | 2013 | 340 | 0.020 |
Why?
| | Sequence Analysis, DNA | 2 | 2005 | 824 | 0.020 |
Why?
| | Fas Ligand Protein | 1 | 2011 | 60 | 0.020 |
Why?
| | Software | 1 | 1996 | 690 | 0.020 |
Why?
| | High-Throughput Screening Assays | 1 | 2012 | 174 | 0.020 |
Why?
| | Drug Synergism | 1 | 2011 | 357 | 0.020 |
Why?
| | Mitochondria | 1 | 1996 | 983 | 0.020 |
Why?
| | Melanoma | 1 | 1996 | 760 | 0.020 |
Why?
| | HIV-1 | 1 | 1995 | 895 | 0.020 |
Why?
| | Brain | 1 | 2021 | 2930 | 0.020 |
Why?
| | Azacitidine | 1 | 1990 | 156 | 0.020 |
Why?
| | Tissue Distribution | 1 | 2009 | 327 | 0.020 |
Why?
| | RNA | 2 | 1993 | 939 | 0.020 |
Why?
| | Organ Size | 1 | 2009 | 462 | 0.020 |
Why?
| | Base Sequence | 2 | 2005 | 2187 | 0.020 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 1996 | 1180 | 0.020 |
Why?
| | Bursa of Fabricius | 1 | 2005 | 2 | 0.010 |
Why?
| | Blotting, Southern | 1 | 2005 | 85 | 0.010 |
Why?
| | Sequence Homology | 1 | 2005 | 43 | 0.010 |
Why?
| | Blotting, Northern | 1 | 2005 | 204 | 0.010 |
Why?
| | Conserved Sequence | 1 | 2005 | 245 | 0.010 |
Why?
| | Sequence Alignment | 1 | 2005 | 366 | 0.010 |
Why?
| | Chromosome Mapping | 1 | 2005 | 509 | 0.010 |
Why?
| | Databases, Genetic | 1 | 2003 | 248 | 0.010 |
Why?
| | Cloning, Molecular | 1 | 2003 | 539 | 0.010 |
Why?
| | Mice, Knockout | 1 | 2009 | 3119 | 0.010 |
Why?
| | HIV Infections | 1 | 1995 | 3079 | 0.010 |
Why?
| | Biological Evolution | 1 | 2003 | 488 | 0.010 |
Why?
| | Genetic Variation | 1 | 2003 | 982 | 0.010 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2005 | 2143 | 0.010 |
Why?
| | Fluorine | 1 | 1996 | 17 | 0.010 |
Why?
| | Chemistry, Physical | 1 | 1996 | 38 | 0.010 |
Why?
| | Chemical Phenomena | 1 | 1996 | 80 | 0.010 |
Why?
| | src Homology Domains | 1 | 1996 | 35 | 0.010 |
Why?
| | Ions | 1 | 1996 | 71 | 0.010 |
Why?
| | Cricetinae | 1 | 1996 | 303 | 0.010 |
Why?
| | Dideoxyadenosine | 1 | 1995 | 3 | 0.010 |
Why?
| | Genes, env | 1 | 1995 | 5 | 0.010 |
Why?
| | Proviruses | 1 | 1995 | 16 | 0.010 |
Why?
| | Lymphocyte Transfusion | 1 | 1995 | 20 | 0.010 |
Why?
| | Lymphocyte Count | 1 | 1995 | 164 | 0.010 |
Why?
| | Viremia | 1 | 1995 | 158 | 0.010 |
Why?
| | Deamination | 1 | 1993 | 6 | 0.010 |
Why?
| | Ligases | 1 | 1993 | 37 | 0.010 |
Why?
| | Middle Aged | 2 | 2013 | 35762 | 0.010 |
Why?
| | DNA, Viral | 1 | 1995 | 358 | 0.010 |
Why?
| | Drug Resistance | 1 | 1993 | 153 | 0.010 |
Why?
| | Immunotherapy, Adoptive | 1 | 1995 | 337 | 0.010 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 1995 | 1217 | 0.000 |
Why?
| | Drug Evaluation | 1 | 1990 | 79 | 0.000 |
Why?
| | Leukopenia | 1 | 1990 | 33 | 0.000 |
Why?
| | Antiviral Agents | 1 | 1995 | 767 | 0.000 |
Why?
| | Neutropenia | 1 | 1990 | 155 | 0.000 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 1995 | 1128 | 0.000 |
Why?
| | Thrombocytopenia | 1 | 1990 | 205 | 0.000 |
Why?
| | Drug Administration Schedule | 1 | 1990 | 778 | 0.000 |
Why?
| | Antibodies, Monoclonal | 1 | 1995 | 1519 | 0.000 |
Why?
| | Aged | 1 | 1990 | 25850 | 0.000 |
Why?
|
|
Ford's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|